U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11NO3
Molecular Weight 169.1778
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PYRIDOXINE

SMILES

CC1=NC=C(CO)C(CO)=C1O

InChI

InChIKey=LXNHXLLTXMVWPM-UHFFFAOYSA-N
InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3

HIDE SMILES / InChI

Molecular Formula C8H11NO3
Molecular Weight 169.1778
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in those receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities. Used for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
8.3 mM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
PYRIDOXINE HYDROCHLORIDE

Cmax

ValueDoseCo-administeredAnalytePopulation
189.6 ng/mL
20 mg 2 times / day multiple, oral
PYRIDOXAL blood
Homo sapiens
58.9 ng/mL
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
62 ng/mL
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
33.1 ng/mL
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
2183.2 nM
100 mg single, intravenous
PYRIDOXAL plasma
Homo sapiens
48.2 ng/mL
20 mg 2 times / day multiple, oral
PYRIDOXINE plasma
Homo sapiens
12.7 ng/mL
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens
38.9 ng/mL
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens
47.1 ng/mL
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens
372.7 nM
100 mg single, intravenous
PYRIDOXINE plasma
Homo sapiens
85.9 ng/mL
20 mg 2 times / day multiple, oral
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
30.1 ng/mL
20 mg single, oral
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
27.4 ng/mL
20 mg single, oral
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
30.2 ng/mL
20 mg single, oral
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
892.9 nM
100 mg single, intravenous
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
1750.3 nM
100 mg single, intravenous
4-PYRIDOXIC ACID plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1511.3 ng × h/mL
20 mg 2 times / day multiple, oral
PYRIDOXAL blood
Homo sapiens
233.6 ng × h/mL
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
244 ng × h/mL
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
249.2 ng × h/mL
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
18603.4 nM × h
100 mg single, intravenous
PYRIDOXAL plasma
Homo sapiens
80 ng × h/mL
20 mg 2 times / day multiple, oral
PYRIDOXINE plasma
Homo sapiens
27 ng × h/mL
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens
35.1 ng × h/mL
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens
42.5 ng × h/mL
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens
2008.9 nM × h
100 mg single, intravenous
PYRIDOXINE plasma
Homo sapiens
1742.3 ng × h/mL
20 mg 2 times / day multiple, oral
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
1076.2 ng × h/mL
20 mg single, oral
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
1021.7 ng × h/mL
20 mg single, oral
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
1064.6 ng × h/mL
20 mg single, oral
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
19420.2 nM × h
100 mg single, intravenous
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
18543.1 nM × h
100 mg single, intravenous
4-PYRIDOXIC ACID plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
8 h
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
12.5 h
20 mg single, oral
PYRIDOXAL blood
Homo sapiens
1.2 h
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens
0.4 h
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens
0.4 h
20 mg single, oral
PYRIDOXINE plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

PubMed

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Dietary Supplement Pyridoxine Deficiency: 10 to 25 mg/day orally, IM, or IV for 3 weeks followed by 2 to 5 mg/day from a multivitamin product. Usual Adult Dose for Anemia Sideroblastic, hereditary: 200 to 600 mg orally daily. If adequate response obtained, dose may be decreased to 30 to 50 mg orally daily.
Route of Administration: Other
In Vitro Use Guide
Pyridoxine (5 mmol/l) caused complete inhibition of microvessel outgrowth in rat aortic rings
Substance Class Chemical
Record UNII
KV2JZ1BI6Z
Record Status Validated (UNII)
Record Version